Evaluation of Methods for the Determination of Chromogranin A in Routine Blood Samples
Patient group: patients with neuroendocrine tumors (active or inactive) Healthy volunteers
Patients:
Interventional
Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
chromogranin A concentration serum
For determination of normal CgA range, we will recruit 60 healthy subjects (30 female, 30 male), in whom a single plasma sample will be obtained for measurement of CgA B For determination of CgA in patients with carcinoid disease (active or inactaive), we wil recruit 200 patients with carcinoid disease from our local neuroendocinre oncology clinic.
single time
No
Stan Van Uum, MD PhD
Principal Investigator
University of Western Ontario, Canada
Canada: Health Canada
HSREB16279
NCT01216267
June 2010
January 2012
Name | Location |
---|